Alexion Pharmaceuticals Inc. (ALXN)

107.42
NASDAQ : Health Technology
Prev Close 115.45
Day Low/High 106.13 / 116.00
52 Wk Low/High 92.56 / 141.86
Avg Volume 1.82M
Exchange NASDAQ
Shares Outstanding 221.29M
Market Cap 25.55B
EPS 0.30
P/E Ratio 8.19
Div & Yield N.A. (N.A)
Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.

Cramer: Why Alexion is Ripe for Deal

Cramer: Why Alexion is Ripe for Deal

Jim Cramer looks at the pop in Alexion on rumors of Roche deal, and why this deal makes sense.

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...

Off the Charts

Off the Charts

We see a lot of short squeezes as money rotates into laggard groups. 

Biotech Makes a Comeback

Biotech Makes a Comeback

Just a natural change in leadership.

Market Takes Aim at Historic Highs Once Again

Market Takes Aim at Historic Highs Once Again

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Off the Charts

Off the Charts

Upward momentum is lagging.

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Mad Money Uncovered: Biomarin and Alexion Orphan Drug Stalwarts

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

Two Long Setups in the Pharma Sector

Two Long Setups in the Pharma Sector

Charts of Actavis and Alexion show a combination of positive technical factors.

Alexion downgraded at Lazard

Rules of the Game: Cranking Out the Green

Rules of the Game: Cranking Out the Green

Here's another batch of names with impressive free cash flow, a crucial metric.

Rules of the Game: Further on Free Cash Flow

Rules of the Game: Further on Free Cash Flow

This metric is a prime indicator of financial health, and these health-related stock stand out.

Fitz Bits: Google Primed to Buy

Fitz Bits: Google Primed to Buy

The stock may now be at a tradable low -- but keep your stop tight.

Two Pharma Stocks Enjoying Good Health

Two Pharma Stocks Enjoying Good Health

These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.

Healthcare Holds Firm

Healthcare Holds Firm

The entire sector did well withstanding Tuesday's decline, but here are a few standouts.

Alexion rated new Neutral at Lazard

Fitz Bits: A Stalwart Uptrend

Fitz Bits: A Stalwart Uptrend

Use this Alexion pullback as a buying opportunity.

The Week Ahead: GDP Data, Earnings

The Week Ahead: GDP Data, Earnings

Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for this week.

Biotech Is a Source of Buys

Biotech Is a Source of Buys

Alexion shows one of the most bullish long-term charts in my database.

Daily Recap of the Charts June 15

Daily Recap of the Charts June 15

Mark Sperling of T3Live review the day's market action and sets up your trading plan for the next session.

Big-Cap Health Care Winners

Big-Cap Health Care Winners

Alexion Pharmaceuticals and Intuitive Surgical are leaders in a top-performing sector.